- Melekel translates an inheritance from a distant past in new album titled Ancient Legacy
- Insure.com Names the Best Auto, Home, Life and Health Insurance Companies for 2023
- Justine Kelly Joins Jenny Craig as Executive Chef and Vice President of Culinary Strategy
SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ -- BioVentrix®, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process of progressive heart failure, today announced the US Food and Drug Administration (FDA) has approved its application for an Expanded Access Program (EAP) for Revivent TC® System.
The BioVentrix Revivent TC System is designed to support a minimally invasive procedure to treat a dilated left ventricle of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and extensive left ventricular scar, who have a suboptimal response to guideline-directed medical therapy. The procedure, referred to as Less Invasive Ventricular Enhancement (LIVE®) therapy, utilizes myocardial micro-anchor implants to reconstruct the dilated left ventricle to produce a more efficient chamber.
More on The Californer
- Two Long Beach COVID-19 Testing and Vaccine Clinics to Relocate and Expand Operations
- Moorpark College to Launch Bachelor's Degree in Applied Biomanufacturing
- LA County Launches Fair Chance Hiring Program to Give System-Impacted Individuals an Equal Chance at Employment
- Workforce Development Board of Ventura County Invites Public Comments On Regional And Local Plans
- SUNCITY ADVISING Selected To Be A Part Of Google Ads Planning Advisory Council
The approval for an Expanded Access Program follows the successful completion of enrollment in the ALIVE (American Less Invasive Ventricular Enhancement) Trial, a prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System. Enrollment in the ALIVE Trial was completed in April 2022.
"The Expanded Access Program is a significant step for BioVentrix as we continue to build our real-world evidence to treat a dilated left ventricle, a maladaptive consequence of cardiac remodeling in ischemic and non-ischemic heart failure," said Jim Dillon, President and CEO of BioVentrix. "Heart failure patients with reduced ejection fraction (HFrEF) that are not responsive to standard-of-care therapies may now have access to LIVE Therapy, currently under investigation."
"While awaiting data analysis and US regulatory submission from the pivotal approval ALIVE Trial, enrollment in the Expanded Access Program will allow ongoing usage of the device and new insights into the predictors and magnitude of improvement of high-risk patients with heart failure undergoing the LIVE Procedure," said Gregg W. Stone, MD, Co-Principal Investigator of the ALIVE Trial, Director of Academic Affairs for the Mount Sinai Heart Health System and Professor of Medicine and Population Health Sciences and Policy at the Icahn School of Medicine at Mount Sinai, New York.
More on The Californer
- My Lineage Proudly Supports Knights of Heroes
- Long Beach: City Announces Visual Improvement Grants Available for Small Businesses Impacted by Crime and Vandalism
- Kettering College Selects YuJa Enterprise Video Platform to Serve Students Pursuing Health Science Education
- $10,000 Grant From Palm Springs Women In Film & Television!s Filmmakers Lab And Stage 32
- 10 reasons why its intelligent to work with a Shopify partner to build Shopify Websites
"Expanded access that permits ongoing usage of this investigational device is critically important," said Jerry D. Estep, MD., Co-Principal Investigator for the ALIVE Trial and Chair of Cardiology, Cleveland Clinic Florida. "Patients with heart failure with high-risk features including significant shortness of breath despite medical management remain at high risk for disease progression and life-threatening events."
BioVentrix, Inc. is a privately held medical device company focused on the development of less invasive therapies to treat the failing left ventricle (LV), the most common cause of heart failure. BioVentrix technologies aim to improve cardiac function by directly addressing LV dilation. The Company markets the Revivent TC System in Europe and is preparing to submit the Premarket Approval (PMA) application to the FDA for the system later this year.
The BioVentrix, LIVE and Revivent TC trademarks are federally registered trademarks owned by BioVentrix. Any unauthorized use is expressly prohibited. Investigational Device.
Limited to Investigational Use Only In The United States.
SOURCE BioVentrix, Inc.
Filed Under: Business
Latest on The Californer
- We're In Paris Is Sidow Sobrino's Newly Released Song and Video
- How we organized a meetup for DevOps engineers
- J:COM Deploys Qwilt's Open Caching Solution to Deliver Superior Digital Experiences Across Japan
- Pine Creek Care Center Responds to Verdict in Rios Suit; Defends Care Provided
- Nautilus Launches "Dr. Prune" Caffeinated Prune Juice
- Tin Mok Appointed to Faraday Future's Board of Directors as an Executive Director
- Abusive Russian to face Pro Wrestling Legend!
- Jim Wilson, Top Notch Realtor in waterfront and beach properties in Redington, Redington Shores, and North Redington Beach, FLorida
- DPFTRAC'S Diesel Particulate Filter (DPF) Cleaning Standards, Procedures, Compliance, EPA 's PM 2.5
- Multi #1 International Best-Selling Author Jennifer S. Wilkov Announces the 2023 April Speak Up Women Conference and Call For Speakers
- JARRARD INC. ADDS RENOWNED HEALTHCARE COMMUNICATIONS EXECUTIVE TO ROSTER
- Ventura College Foundation Provides $776,264 Direct Student Support During 2021-2022 Academic Year
- California: State Water Project to Increase Expected 2023 Deliveries
- RealDefense Acquires SUPERAntiSpyware From Support.com
- Creators Society Animation Podcast Launches Season 3 With An Interview With Kristine Belson, President Of Sony Pictures Animation
- The King of Urban Content Introduces EVERYWHERE Theater
- The Mogharebi Group Brokers $7.25 Million Sale of Costa Mesa, CA Multifamily Community
- San Jose: : San José Celebrates Over $62 Million in Grants for Transportation Safety
- Elden Ring, Stray, God of War Ragnarök, and Pentiment Lead Finalists for the 23rd Annual Game Developers Choice Awards
- Verb Presents Welcomes Josh Dean, Author of The Taking of K-129, The Most Daring Covert Operation in US History